Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
144 participants
INTERVENTIONAL
2023-06-08
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Response Modulation Hypothesis of Socioemotional Processing Associated With Alcohol Use Disorder
NCT03535129
Oxytocin and Stress Response in Alcohol Use Disorder
NCT03610633
Multimodal Neuroimaging of Alcohol Cues, Cortisol Response, and Compulsive Motivation
NCT04412824
The Effect of Positive and Negative Emotions on Brain Activity in Alcoholics and Nonalcoholics
NCT00001675
Neural Substrates of Approach-Avoidance Conflict
NCT02119624
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral alcohol drink
Alcohol (Ethanol)
95% Ethanol diluted in Grape-flavored drink
Placebo (non-alcohol drink)
Placebo
Grape-flavored drink
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alcohol (Ethanol)
95% Ethanol diluted in Grape-flavored drink
Placebo
Grape-flavored drink
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Consumes \> 10 drinks/week or reports binge drinking at least once a month, and is not in, or currently seeking, treatment for AUD.
3. PCL-SV psychopathy score \< 18
4. Able/willing to abstain from alcohol for 24 hours before MRI scanning.
5. Physically healthy (confirmed by comprehensive medical history and physical exam) and does not have metal implants, plates, or screws in body or head (MRI safety issue).
6. If a smoker, consumes no more than 15 cigarettes per day.
7. Able to give informed consent.
1. Life History of Aggression (LHA) score \> 12
2. In addition AGG participants must report:
1. Current history of at least two (2) angry outbursts a week (on average) for the past three months and/or three significant angry aggressive outbursts in which other people are assaulted and/or property is damaged in the past year.
2. Angry outbursts are out of proportion to provocation and not associated with a tangible goal (not premeditated).
3. Angry outbursts are associated with distress and/or impairment;
4. Angry outbursts do not occur exclusively during another disorder or condition.
3. No lifetime history of AUD (from DSM-5 criteria).
1. Meets DSM-5 criteria for alcohol use disorder (AUD) without significant history of alcohol withdrawal, seizures, or delirium tremens.
2. Consumes \> 10 drinks/week or reports binge drinking at least once a month, and is not in, or currently seeking, treatment for AUD.
1. Does not meet DSM-5 criteria for current or past alcohol use disorder (AUD).
2. LHA score is less than 12.
3. Does not meet DSM-5 Criteria for a current, or past, major psychiatric disorder.
Exclusion Criteria
3\) Life history of bipolar disorder, schizophrenia, organic mental syndrome or intellectual deficiency (i.e., IQ \< 70 by WRAT).
4\) Drug screen positive for amphetamines, barbituates, benzodiazepines, cocaine, phencyclidine, or opiates.
5\) Positive urine pregnancy test 6) Clinically significant medical condition (current and active medical condition requiring daily prescribed medication).
7\) PCL-SV psychopathy score \> 18 (see above). 8) Score \> 8 on the Clinical Institute Withdrawal Assessment-Revised (CIWA-Ar).
9\) Treatment with antipsychotic medications within two weeks of study entry. 10) Current suicidal ideation. 11) Metal in body, history of \> 5 min loss of consciousness, left-handedness or body weight \> 300lbs (fMRI exclusions).
12\) Unable/unwilling to abstain from alcohol for 24 hours and recreational drugs for 48 hours prior to session arrival.
13\) Unable to comply with study procedures. 14) Unable to sign informed consent document. 15) Taking of anticoagulants. 16) Drinks less than 2 drinks per week 17) Has not had a binge drinking episode (5+ for men, 4+ for women) in the past 3 months.
21 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Ohio State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Emil Coccaro
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emil Coccaro, M.D.
Role: PRINCIPAL_INVESTIGATOR
Ohio State University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020H0369
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.